Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation

Neuro-Oncology

Volumn 15, Issue 10, 2013, Pages 1405-1412

  Wick, Wolfgang ^a,b   Steinbach, Joachim P ^c   Platten, Michael ^a   Hartmann, Christian ^a,b,d   Wenz, Frederik ^e   Von Deimling, Andreas ^a,b   Shei, Peipei ^f   Moreau Donnet, Valerie ^g   Stoffregen, Clemens ^h   Combs, Stephanie E ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f ELI LILLY AND COMPANY   (United States)

^g Lilly France ^*  (France)

^h LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

brain tumors; enzastaurin; glioblastoma; MGMT; radiotherapy

Indexed keywords

ENZASTAURIN; GADOLINIUM; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ALOPECIA; ARTICLE; BRAIN BIOPSY; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN SURGERY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; CONTRAST ENHANCEMENT; CONVULSION; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; EMPYEMA; FATIGUE; FEMALE; FOLLOW UP; GLIOBLASTOMA; HEALING IMPAIRMENT; HEART VENTRICLE FIBRILLATION; HEMIPARESIS; HUMAN; HYPONATREMIA; IATROGENIC DISEASE; INTRACRANIAL TUMOR; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; LUNG EMBOLISM; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTOSIS; PNEUMONIA; PROGRESSION FREE SURVIVAL; RADIATION DERMATITIS; RADIATION FIELD; SEPSIS; SIDE EFFECT; THROMBOSIS; TUMOR BIOPSY; TUMOR BLEEDING; URINE COLOR; VERTIGO; VOMITING; WOUND INFECTION;

BRAIN TUMORS; ENZASTAURIN; GLIOBLASTOMA; MGMT; RADIOTHERAPY;

ADULT; AGED; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 84885009230     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not100     Document Type: Article

References (27)

1. Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol. 2010;67(3):279-283.
2. Preusser M, de Ribaupierre S,Wohrer A, et al. Current concepts and management of glioblastoma. Ann Neurol. 2011;70(1):9-21.
3. Hess KR. Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol. 1999;42(3):227-231. (Pubitemid 29322199)
4. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys. 1979;5(10):1725-1731. (Pubitemid 10187518)
5. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. (Pubitemid 40349501)
6. Stupp R, Hegi ME, MasonWP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
7. Silber JR, Bobola MS, Blank A, Chamberlain MC. O(6)-methylguanine- DNA methyltransferase in glioma therapy: promise and problems. Biochim Biophys Acta. 2012;1826(1):71-82.
8. vonDeimling A, KorshunovA, HartmannC. Thenext generationof glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol. 2011;21(1):74-87.
9. Weller M, Stupp R, Reifenberger G, et al.MGMTpromotermethylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010;6(1):39-51.
10. Chen YB, LaCasce AS. Enzastaurin. Expert Opin Investig Drugs. 2008;17(6):939-944.
11. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase C beta-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005;65(16):7462-7469. (Pubitemid 41161281)
12. Keyes KA, Mann L, Sherman M, et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol. 2004;53(2):133-140. (Pubitemid 38186992)
13. Tabatabai G, Frank B, WickA, et al. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann Neurol. 2007;61(2):153-161. (Pubitemid 46363842)
14. Willey CD, Xiao D, Tu T, et al. Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation. Int J Radiat Oncol Biol Phys. 2010;77(5):1518-1526.
15. CarducciMA,Musib L, Kies MS, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol. 2006;24(25):4092-4099. (Pubitemid 46622284)
16. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59(4):793-797. (Pubitemid 29086728)
17. HegiME,DiserensAC,GorliaT, etal.MGMTgenesilencingandbenefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10): 997-1003.
18. Vlassenbroeck I, Califice S, Diserens AC, et al. Validation of real-time MSP to determine MGMT promoter methylation in glioma. J Mol Diagn. 2008;10:332-337.
19. Galanis E,WuW, CloughesyT, et al. Phase2trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. 2012;13(5):e196-e204.
20. Reardon DA, Galanis E, DeGroot JF, et al. Clinical trial end points for highgrade glioma: the evolving landscape.NeuroOncol. 2011;13(3): 353-361.
21. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280. (Pubitemid 20195640)
22. WickW, Hartmann C, EngelC, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27(35):5874-5880.
23. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28(7):1168-1174.
24. WickW, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707-715.
25. Minniti G, Lanzetta G, Scaringi C, et al. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int JRadiatOncol Biol Phys. 2012;83(1):93-99.
26. Stummer W, Meinel T, Ewelt C, et al. Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J Neurooncol. 2012;108(1):89-97.
27. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro- Oncology working group. J Clin Oncol. 2010;28(11):1963-1972.